A method based on capillary electrophoresis has been developed for the analysis of the novel antidepressant drug duloxetine in human plasma. The method makes use of laser-induced fluorescence detection after derivatisation of the analyte with 5-(4,6-dichlorotriazinyl)aminofluorescein at pH 11. A single step liquid/liquid extraction procedure with a mixture of hexane/2-propanol allows the sample clean-up with extraction yields always >or=84% and interference removal. The electrophoretic separation is achieved using uncoated fused silica capillaries (60.0 cm effective length, 75.0 cm total length, 50 microm internal diameter) and a background electrolyte composed of borate buffer (40 mM, pH 10.3), tetrabutylammonium bromide (10 mM), and acetone (10%, v/v). The applied voltage is 20 kV; the samples are injected by pressure (50 mbar x 8 s). The method has been fully validated in terms of linearity range (2.5-150 ng mL(-1)), LOD and LOQ (1.0 and 2.5 ng mL(-1), respectively), precision (R.S.D.<6.7%) and accuracy (recovery >78%). Application to samples obtained from patients under treatment with duloxetine gave good results. The method represents the first application of capillary electrophoresis to the analysis of duloxetine in human plasma.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jchromb.2009.02.059 | DOI Listing |
Cureus
December 2024
Family Medicine, Holy Family Hospital, Rawalpindi, PAK.
Introduction Fibromyalgia is a chronic pain disorder characterized by widespread pain, fatigue, and sleep disturbances. The purpose of this study was to compare how well duloxetine, pregabalin, and milnacipran worked for fibromyalgia patients in terms of pain management, quality of life, and sleep quality. Methodology A prospective cohort research study with 193 fibromyalgia patients was carried out at the Abbas Institute of Medical Sciences, Muzaffarabad, Pakistan.
View Article and Find Full Text PDFBMJ Open
December 2024
Institute for Musculoskeletal Health, Sydney Local Health District, Sydney, New South Wales, Australia.
Introduction: Sciatica is a debilitating condition that often becomes chronic, and for which there are few effective treatment options. Treatments such as the anti-depressant duloxetine have shown promise, but the evidence is inconclusive. We are describing a high quality, definitive trial to investigate the efficacy, safety and cost-effectiveness of duloxetine in chronic sciatica.
View Article and Find Full Text PDFBrain Behav
January 2025
Department of Surgery, Medical College, King Faisal University, Hofuf, Ahsa, Saudi Arabia.
Background: Duloxetine, a serotonin and norepinephrine reuptake inhibitor (SNRI), is used to treat various health conditions, including major depressive disorder, generalized anxiety disorder, fibromyalgia, and off-label for chemotherapy-induced pain. We conducted this systematic review and meta-analysis aiming to test the current evidence regarding effectiveness and safety of duloxetine for postspine surgeries pain.
Methods: We searched the Cochrane Central Register of Controlled Trials, PubMed, Scopus and Web of science databases for relevant articles up to March 2024.
Cureus
November 2024
Psychology, Maudsley Health, Al Amal Psychiatric Hospital, Dubai, ARE.
This case report discusses the treatment of a 42-year-old male with over a decade of treatment-resistant obsessive-compulsive disorder (OCD) and comorbid major depressive disorder (MDD). The patient underwent various pharmacological and psychotherapeutic treatments, including multiple antidepressants and cognitive-behavioral therapy (CBT), yet experienced only partial symptom relief. At baseline, the patient's depressive symptoms were severe, with a Hamilton Depression Rating Scale (HAM-D) score of 28, and his obsessive-compulsive symptoms were marked, with a Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score of 34.
View Article and Find Full Text PDFEur J Pain
January 2025
Healthy Working Lives Research Group, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!